Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1

Volume: 27, Issue: 12, Pages: 1851 - 1855
Published: Dec 1, 2021
Abstract
The immunogenicity and safety of the Pfizer-BioNTech BNT162b2 mRNA vaccine in people living with human immunodeficiency virus type 1 (PLWH) are unknown. We aimed to assess the immunogenicity and safety of this vaccine in PLWH.In this prospective open study, we enrolled 143 PLWH, aged ≥18 years, who attended our clinic and 261 immunocompetent health-care workers (HCWs). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding...
Paper Details
Title
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
Published Date
Dec 1, 2021
Volume
27
Issue
12
Pages
1851 - 1855
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.